At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
02142 HBM HOLDINGS-B
Closed 12-19 16:08:06
13.340
+0.830
+6.63%
High13.560Low12.450Vol6.94M
Open12.450D1 Closing12.510Amplitude8.87%
Mkt Cap11.61BTradable Cap11.61BTotal Shares870.56M
T/O92.29MT/O Rate0.80%Tradable Shares870.56M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Disclaimer: HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its absolute accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.
HK Stock Movement | HBM Holdings-B (02142) Surges Over 8% in Early Trading on $1B+ BD Deal with Bristol-Myers Squibb
Stock News  ·  10:32
HK Stock Movement | HBM Holdings-B (02142) Surges Over 8% in Early Trading on $1B+ BD Deal with Bristol-Myers Squibb
HK Stock Movement | HBM HOLDINGS-B (02142) Still Down 2% After Signing Global Strategic Collaboration with Bristol-Myers Squibb, Potential Earnings Exceed $1 Billion
Stock News  ·  12-17 10:10
HK Stock Movement | HBM HOLDINGS-B (02142) Still Down 2% After Signing Global Strategic Collaboration with Bristol-Myers Squibb, Potential Earnings Exceed $1 Billion
Hbm Holdings Enters Global Strategic Collaboration And License Agreement With Bristol Myers Squibb
Reuters  ·  12-17 09:22
Hbm Holdings Enters Global Strategic Collaboration And License Agreement With Bristol Myers Squibb
HBM Holdings and Bristol Myers Squibb Sign Global Strategic Collaboration Agreement
Reuters  ·  12-17 08:00
HBM Holdings and Bristol Myers Squibb Sign Global Strategic Collaboration Agreement
Hbm Holdings - Entering Into Global Strategic Collaboration and License Agreement With Bristol Myers Squibb
THOMSON REUTERS  ·  12-17 08:00
Hbm Holdings - Entering Into Global Strategic Collaboration and License Agreement With Bristol Myers Squibb
Hbm Holdings - Under Deal, Co to Collaborate to Advance and Accelerate Multi-Specific Antibody Discovery Programs
THOMSON REUTERS  ·  12-17 08:00
Hbm Holdings - Under Deal, Co to Collaborate to Advance and Accelerate Multi-Specific Antibody Discovery Programs
Hbm Holdings - Could Receive Payments Totaling $90 Mln & Development and Commercial Milestones of up to $1,035 Mln Under Deal
THOMSON REUTERS  ·  12-17 08:00
Hbm Holdings - Could Receive Payments Totaling $90 Mln & Development and Commercial Milestones of up to $1,035 Mln Under Deal
Declining Stock and Solid Fundamentals: Is The Market Wrong About HBM Holdings Limited (HKG:2142)?
Simply Wall St.  ·  12-17 07:23
Declining Stock and Solid Fundamentals: Is The Market Wrong About HBM Holdings Limited (HKG:2142)?
HBM Holdings Repurchases 400,000 Shares at HK$13 Each in HKEX Filing
Reuters  ·  12-15
HBM Holdings Repurchases 400,000 Shares at HK$13 Each in HKEX Filing
HBM Holdings Repurchases 200,000 Shares at HK$13.65 Each in HKEX Filing
Reuters  ·  12-08
HBM Holdings Repurchases 200,000 Shares at HK$13.65 Each in HKEX Filing
HBM HOLDINGS-B (02142) Repurchases 100,000 Shares for HK$1.3992 Million on December 5
Stock News  ·  12-05
HBM HOLDINGS-B (02142) Repurchases 100,000 Shares for HK$1.3992 Million on December 5
HBM Holdings Repurchases 100,000 Shares for HKD 1.4 Million in HKEX Filing
Reuters  ·  12-05
HBM Holdings Repurchases 100,000 Shares for HKD 1.4 Million in HKEX Filing
10th Zhitong Capital Market Annual Conference Honors Excellence with 25 Awards Unveiled
Stock News  ·  12-03
10th Zhitong Capital Market Annual Conference Honors Excellence with 25 Awards Unveiled
HK Stock Movement | HBM HOLDINGS-B (02142) Rises Nearly 4% in Afternoon Trading as Company Deepens Global Strategic Collaboration with AstraZeneca
Stock News  ·  12-02
HK Stock Movement | HBM HOLDINGS-B (02142) Rises Nearly 4% in Afternoon Trading as Company Deepens Global Strategic Collaboration with AstraZeneca
HBM Holdings (02142) Announces Share Repurchases and Share Issuances Under Award Scheme
Bulletin Express  ·  11-28
HBM Holdings (02142) Announces Share Repurchases and Share Issuances Under Award Scheme
HBM HOLDINGS-B (02142) Repurchases 100,000 Shares for HK$1.337 Million on November 28
Stock News  ·  11-28
HBM HOLDINGS-B (02142) Repurchases 100,000 Shares for HK$1.337 Million on November 28
HBM Holdings Repurchases 100,000 Shares at HK$13.53 Each, Files Disclosure with HKEX
Reuters  ·  11-28
HBM Holdings Repurchases 100,000 Shares at HK$13.53 Each, Files Disclosure with HKEX
HBM HOLDINGS-B (02142) Rises Over 4% Again on Deepened Collaboration with AstraZeneca for Next-Gen Oncology Therapies
Stock News  ·  11-27
HBM HOLDINGS-B (02142) Rises Over 4% Again on Deepened Collaboration with AstraZeneca for Next-Gen Oncology Therapies
HBM Holdings-B (02142) Rises Nearly 5% as Collaboration with AstraZeneca Expands to Develop ADC and T-cell Engager Therapies
Stock News  ·  11-25
HBM Holdings-B (02142) Rises Nearly 5% as Collaboration with AstraZeneca Expands to Develop ADC and T-cell Engager Therapies
BUZZ-Hbm climbs on progress of AstraZeneca collaboration
Reuters  ·  11-24
BUZZ-Hbm climbs on progress of AstraZeneca collaboration
No data available

Introduction

Company Name.
HBM HOLDINGS-B
Affiliated Markets:
SEHK
Listing Date:
--
Main Business:
Hbm Holdings Ltd is an investment holding company mainly engaged in the business of developing therapeutics in the fields of immuno-oncology and immunology diseases. The Company's products include HBM9161, HBM4003, HBM7008 and HBM1020. Batoclimab (HBM9161) is mainly used for immune thrombocytopenia (ITP), graves’ ophthalmopathy (GO), myasthenia gravis (MG), neuromyelitis optica spectrum disorder (NMOSD). Tanfanercept (HBM9036) is mainly used for dry eye disease (DED). The Company also researches and develops immuno-oncology portfolio, including internally developed next generation immune-oncology assets targeting immune-desert, immune-excluded and inflamed tumors. The Company owns Harbour Mice Platform, generating fully human monoclonal antibodies in the classical two heavy and two light chain H2L2 format as well as heavy chain only (HCAb) format.
Issue price:
--